Medical, a division of Tilray Brands, announced the launch of its first commercial German grown medical cannabis flowers from its ...

Separately, Roth Mkm reduced their price target on shares of Tilray from $2.00 to $1.75 and set a “neutral” rating on the stock in a research report on Friday, October 11th. Shares of NASDAQ TLRY ...

Shares of Tilray Brands Inc. TLRY shed 2.04% to $1.44 Wednesday, on what proved to be an all-around mixed trading session for ...

Tilray Brands stock resumed the downward trend and crashed to its all-time low after suffering a major setback in the United ...

Charting, Price Performance, News & Related Contracts.

Its third quarter results are in the books and Beacon Securities analyst Doug Cooper still thinks there is money to be made ...

Canopy Growth's revenue and EBITDA have been disappointing, and analysts' projections for FY25 and FY26 remain weak. Read why ...

Q1 was way below expectations, and the outlook has been diminished. The stock looks expensive to peers. Find out why TLRY ...

TILRAY BRANDS INC (TLRY) is a small-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 70% based on the firm’s underlying fundamentals and the stock’s ...

As election day approaches, they face volatility amid Trump's rising poll numbers and market skepticism about his stance.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Zuanic & Associates rates Tilray "Neutral," noting long-term potential but near-term uncertainties, despite cannabis growth ...